Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Jardiance® Novel Therapy Developed for the Treatment of Patients with Heart Failure

Eli Lilly and Company in combination with Boehringer Ingelheim has developed Jardiance®, a novel therapy to treat patients with heart failure with preserved ejection fraction (HFpEF).

Jardiance is used to lower the blood sugar levels along with diet and exercise in adults with type 2 diabetes, lessens the risk of cardiovascular death in adults with type 2 diabetes and also reduces the risk of hospitalisation for heart failure.

In EMPEROR-Preserved phase III trial, Jardiance has shown 21 per cent of risk reduction of cardiovascular death or hospitalisation for heart failure adults with preserved ejection fraction when compared with placebo.

Some of the common side effects caused by Jardiance® are Ketoacidosis, Dehydration, severe urinary tract infections, low blood sugar, Necrotizing fasciitis, Vaginal yeast infection and allergy.

U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy designation for Jardiance® (empagliflozin) to treat adults with HFpEF.

In US, HFpEF leads for more than 6 million heart failure cases. Currently there are no treatments available which shows significant improvement for patients with HFpEF.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024